Category Archives: Gene Therapy

By RTT News, April 06, 2015, 01:21:00 PM EDT (RTTNews.com) - Shares of uniQure N.V. ( QURE ) surged 46 percent on Monday after announcing a collaboration with Bristol-Myers Squibb Co ( BMY ) for cardiovascular diseases-related gene therapy. The deal will see Bristol-Myers initially acquiring a 4.9 percent stake in uniQure and making near-term payments of $100 million. The collaboration is to be effective during the second quarter of 2015. The deal provides Bristol-Myers with exclusive access to uniQure's gene therapy platform for multiple targets in cardiovascular diseases. Bristol-Myers will initially buy a 4.9 percent stake in uniQure for $33.84 per share, or at least $32 million in total. The $33.84 per share represents a premium of 48 percent to uniQure's closing on Thursday. Bristol-Myers will acquire an additional 5 percent stake in uniQure before the end of this year at a 10 percent premium, and will be granted two warrants to acquire up to an additional 10 percent equity interest, at a premium, based on additional targets being introduced into the collaboration. Bristol-Myers will make near-term payments of about $100 million, including an upfront payment of $50 million at the closing of the transaction, a $15 million payment … Continue reading →

NEW YORK (MarketWatch) -- Shares of UniQure NV QURE, +47.03% soared 44% in premarket trade Monday, after the gene therapy company announced a collaboration deal with Bristol-Myers Squibb BMY, -0.36% which includes Bristol-Myers acquiring an initial equity stake of 4.9% in UniQure. The stake will be acquired at $33.84 per share, which is 48% above Thursday's closing price of $22.86, UniQure said. Under terms of the agreement, which will give Bristol-Myers exclusive access to UniQure's gene therapy technology for multiple targets in cardiovascular diseases, Bristol-Myers will acquire an additional 5% stake in UniQure by Dec. 31, 2015 at a 10% premium, and will be granted warrants to buy up to an additional 10% stake. Bristol-Myers will also make an upfront payment of $50 million and a $15 million payment for the selection of three collaboration targets. UniQure's stock has surged 54% year to date through Thursday and Bristol-Myers has climbed 7.1%, while the S&P 500 has gained 0.4%. Read more here: UniQure's stock soars after Bristol-Myers Squibb deal to buy a large stake … Continue reading →

NEW YORK ( TheStreet) -- Shares of UniQure NV (QURE)soared more than 50% to a 52-week high of $35.50in morning trading Monday after Bristol-Myers Squibbinvested in the Dutch company to collaborate on gene therapies for cardiovascular disease. Bristol-Myers will have exclusive access to UniQure's proprietary gene therapy program for congestive heart failure. The two companies will collaborate on 10 targets and could also work on more projects for other diseases in the future. Bristol-Myers will pay approximately$100 million, including an upfront payment of $50 million, a $15 million payment to select two collaboration targets, and a $32 million investment in UniQure for a 4.9% stake in the Dutch company. Bristol-Myers will earn an additional 5% ownership before the end of the year at a 10% premium. UniQure is eligible toreceive at least an additional $254 million if certain milestones are reached. It can also receive $217 million for other gene therapy products. See more here: UniQure NV (QURE) Stock Soars to 52-Week High on Bristol-Myers Squibb Investment … Continue reading →

Gene Therapy Delivery: What Can be Accomplished with Existing Vector Technology? Moderator: Joshua Schimmer, M.D., Managing Director Senior Research Analyst, Piper Jaffray Speakers: David Kirn, M.D., CEO Co-Founder, 4D Molecular Therapeutics Richard Lawn, Ph.D., ... By: Alliance for Regenerative Medicine … Continue reading →

From left: Tushar Menon, Inder Verma and Amy Firth. Salk Institute From left: Tushar Menon, Inder Verma and Amy Firth. / Salk Institute Those born with the immune disorder SCID-X1, or "bubble boy disease" may one day benefit from a new treatment to give them a functioning immune system, if new research from the Salk Institute succeeds. Working with cultures of induced pluripotent stem cells from a patient, Salk scientists led by gene therapy expert Inder Verma repaired the genetic defect that causes the disease. Infants born with this inherited condition have virtually no immune resistance, and can be killed by infections easily defeated by normal immune systems. Researchers were able to generate what appear to be mature NK, or "natural killer" immune cells, the first time this has been done. They also generated progenitors of T cells. This doesn't repair all the immune system, but it's a big step in that direction. These preliminary results may pave the way to an alternative from treating these patients, Verma said. At present, patients can be treated with bone marrow transplants, but matching donors are hard to find. Gene therapy using a viral vector to repair the defect has been successful, but … Continue reading →

Strike Force Heroes 2 - Mission.10 "Gene Therapy" Iagi By: AntilTheIkaring … Continue reading →

bluebird bio Jim DeTore, CFO (NASDAQ: BLUE) Headquarters: Cambridge, MA With its lentiviral-based gene therapy and gene editing capabilities, bluebird bio has built an integrated product platform with... By: Alliance for Regenerative Medicine … Continue reading →

Gene therapy slows vision loss in mouse models Harvard Medical School genetics professor Connie Cepko and postdoctoral researcher Wenjun Xiong talk about developing a gene therapy to stave off blindness. Read the full story at http://hms.harva. By: Harvard Medical School … Continue reading →

DNA GENE THERAPY Vision restored to patient with DNA GENE THERAPY. By: sunita agarwal … Continue reading →